A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: ...
The global image-guided therapy systems market is anticipated to grow at a steady compound annual growth rate of approximately 5% during the forecast period. This growth is largely attributed to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results